{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T20:12:08Z","timestamp":1779912728173,"version":"3.53.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2016,8,3]],"date-time":"2016-08-03T00:00:00Z","timestamp":1470182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1038\/leu.2016.220","type":"journal-article","created":{"date-parts":[[2016,8,3]],"date-time":"2016-08-03T02:46:46Z","timestamp":1470192406000},"page":"2396-2397","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Chronic myeloid leukemia patients call for quality and consistency when generics are introduced to treat their cancer"],"prefix":"10.1038","volume":"30","author":[{"name":"for the CML Advocates Network","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Geissler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Sharf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Cugurovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Padua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0160","family":"Narbutas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Remic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Venkatesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,3]]},"reference":[{"key":"BFleu2016220_CR1","doi-asserted-by":"publisher","first-page":"164","DOI":"10.4103\/0971-5851.123716","volume":"34","author":"P Parikh","year":"2013","unstructured":"Parikh P . Report of chronic myeloid leukemia in chronic phase from Tata Memorial Hospital, Mumbai, 2002-2008. Indian J Med Paediatr Oncol 2013; 34: 164\u2013167.","journal-title":"Indian J Med Paediatr Oncol"},{"key":"BFleu2016220_CR2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.5639\/gabij.2014.0302.021","volume":"3","author":"B Haas","year":"2014","unstructured":"Haas B, Unkrig C, Naumann-Winter F, Enzmann H, Potthast H, R\u00f6per L et al. Tyrosine kinase inhibitors becoming generic drugs \u2013 risks and chances from a regulatory perspective. GaBI J 2014; 3: 79\u201387.","journal-title":"GaBI J"},{"key":"BFleu2016220_CR3","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1248\/bpb.b14-00652","volume":"38","author":"M Yokoo","year":"2015","unstructured":"Yokoo M, Kubota Y, Tabe Y, Kimura S . Comparative study of the anti-leukemic effects of imatinib mesylate, Glivec tablet and its generic formulation, OHK9511. Biol Pharm Bull 2015; 38: 411\u2013416.","journal-title":"Biol Pharm Bull"},{"key":"BFleu2016220_CR4","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1177\/1078155214522143","volume":"21","author":"ML de Lemos","year":"2015","unstructured":"de Lemos ML, Kyritsis V . Clinical efficacy of generic imatinib. J Oncol Pharm Pract 2015; 21: 76\u201379.","journal-title":"J Oncol Pharm Pract"},{"key":"BFleu2016220_CR5","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.3109\/10428194.2014.921299","volume":"55","author":"V Mathews","year":"2014","unstructured":"Mathews V . Generic imatinib: the real-deal or just a deal? Leuk Lymphoma 2014; 55: 2678\u20132680.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2016220_CR6","doi-asserted-by":"publisher","first-page":"7112","DOI":"10.1186\/1752-1947-3-7112","volume":"29","author":"HA Goubran","year":"2009","unstructured":"Goubran HA . Failure of a non-authorized copy product to maintain response achieved with imatinib in a patient with chronic phase chronic myeloid leukemia: a case report. J Med Case Rep 2009; 29: 7112\u20137114.","journal-title":"J Med Case Rep"},{"key":"BFleu2016220_CR7","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1159\/000319150","volume":"3","author":"Z Chouffai","year":"2010","unstructured":"Chouffai Z . Hematologic relapse after 2 years on a non-authorized copy version of imatinib in a patient with chronic myeloid leukemia in chronic phase: a case report. Case Rep Oncol 2010; 3: 272\u2013276.","journal-title":"Case Rep Oncol"},{"key":"BFleu2016220_CR8","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s12185-009-0431-1","volume":"91","author":"M Mattar","year":"2010","unstructured":"Mattar M . Failure of copy Imatib (CIPLA, India) to maintain hematologic and cytogenetic responses in chronic myeloid leukemia in chronic phase. Int J Hematol 2010; 91: 104\u2013106.","journal-title":"Int J Hematol"},{"issue":"Suppl","key":"BFleu2016220_CR9","doi-asserted-by":"publisher","first-page":"(abstract e1802","DOI":"10.1200\/jco.2015.33.15_suppl.e18024","volume":"33","author":"F Demirkan","year":"2015","unstructured":"Demirkan F, Sevindik OGG, Karaman A, Alacacioglu I, Solmaz SM, Ozsan GH . Comparing the efficacy of generic Imatinib formulations with the original Imatinib as the frontline tyrosine kinase inhibitor in chronic phase chronic myeloid leukemia. J Clin Oncol 2015; 33 (Suppl): (abstract e18024).","journal-title":"J Clin Oncol"},{"key":"BFleu2016220_CR10","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1016\/j.clinthera.2009.10.009","volume":"31","author":"S Parrillo-Campiglia","year":"2009","unstructured":"Parrillo-Campiglia S, Ercoli MC, Umpierrez O, Rodr\u00edguez P, M\u00e1rquez S, Guarneri C et al. Bioequivalence of two film-coated tablets of imatinib mesylate 400\u2009mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers. Clin Ther 2009; 31: 2224\u20132232.","journal-title":"Clin Ther"},{"key":"BFleu2016220_CR11","doi-asserted-by":"publisher","first-page":"9342","DOI":"10.1186\/1757-1626-2-9342","volume":"2","author":"IA Asfour","year":"2009","unstructured":"Asfour IA, Elshazly SA . Changing therapy from Glivec(R) to a \"copy\" imatinib results in a worsening of chronic myeloid leukemia disease status: two case reports. Cases J 2009; 2: 9342\u20139345.","journal-title":"Cases J"},{"key":"BFleu2016220_CR12","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122: 872\u2013884.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu2016220.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2016220","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2016220.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T14:05:52Z","timestamp":1684418752000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2016220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,3]]},"references-count":12,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["BFleu2016220"],"URL":"https:\/\/doi.org\/10.1038\/leu.2016.220","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,3]]},"assertion":[{"value":"3 August 2016","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2016","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GS: patient advisor to Ariad, Novartis, BMS and Pfizer. JG: patient advisor to Ariad, Novartis, BMS and Pfizer. JC: patient advisor to Novartis and Pfizer. RP: patient advisor to Novartis. \u0160N: patient advisor to Novartis and Pfizer. MR and VV: none.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}